Casgevy Eligibility Reportedly Lowered to Age 2, Bringing CRISPR Therapy Into the Imagination of Earlier Pediatric Care
If this approval is confirmed by complete regulatory documents, gene-editing treatment for sickle cell disease will no longer be an option only for adolescents and adults; the real test will lie in pediatric safety, the transplant process, and access to care.